TwinStrand Biosciences Stock
TwinStrand Biosciences develops and commercializes the Duplex Sequencing™ technology for DNA sequencing.
Sign up today and learn more about TwinStrand Biosciences Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About TwinStrand Biosciences Stock
TwinStrand Biosciences improves the accuracy of DNA sequencing by >10,000 fold and allows detection of mutations that are invisible by other approaches, through its technology. Its technology, Duplex Sequencing, is based on research and has potential applications in a wide range of fields, including oncology, infectious disease, organ transplantation, reproductive and genetic health, and forensics. TwinStrand Biosciences holds an exclusive worldwide license to develop and commercialize Duplex Sequencing. It was founded in 2015 and is headquartered in Bellevue, Washington.
Funding History
| June 2016 | $1.9M |
|---|---|
| September 2017 | $5.3M |
| January 2020 | $16.0M |
Management
Chief Legal Officer
Jeff Grainger
Co-Founder & Chief Scientific Officer
Jesse Salk
Chief Operating Officer
Elena Cant
Chief Executive Officer
Jesse Salk
Press
patents - Apr, 14 2024
Reagents and adapters for nucleic acid sequencing and methods for making such …patents - Apr, 14 2024
Methods and reagents for characterizing genomic editing, clonal expansion, and …patents - Apr, 14 2024
Genomics alignment probability score rescalerpatents - Apr, 14 2024
Methods and reagents for detection of circular dna molecules in biological …EquityZen Recognized As:
